(Q41206503)

28 September 2017

1 reference

title

Acarbose: its role in the treatment of diabetes mellitus (English)

1 reference

28 September 2017

L K Campbell

1

1 reference

28 September 2017

J R White

series ordinal

2

1 reference

28 September 2017

R K Campbell

series ordinal

3

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 November 1996

1 reference

Annals of Pharmacotherapy

28 September 2017

1 reference

28 September 2017

30

1 reference

28 September 2017

11

1 reference

28 September 2017

1255-1262

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

28 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Double-blind Crossover Study of Acarbose in Type 1 Diabetic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Significance of testing platelet functions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Comparative tolerability profiles of oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Acarbose and nutrient intake in non-insulin dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Antihyperglycaemic agents. Drug interactions of clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Management of Insulin-Dependent Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Safety Profile of Acarbose, an α-Glucosidase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

Nutritional Recommendations for Diabetic Patients and Treatment with α-Glucosidase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001110

10.1177/106002809603001110

21 January 2018

Identifiers

DOI

1 reference

release_5z7sz7jf7jfhdej6bito3au65y

28 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5z7sz7jf7jfhdej6bito3au65y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference